In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Of all the wonder drugs in the history of medicine, insulin may be the closest parallel, in both function and purpose, to this century’s miracle of a metabolic drug: the GLP-1 agonist.

Global Partners LP (GLP) reports significant gains in key financial metrics and strategic expansions, despite rising expenses. WALTHAM, Mass., November 08, 2024--Global Partners LP (NYSE ...

Opens in a new tab or window SAN DIEGO -- Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a GLP-1 receptor agonist, regardless of their obesity ...